Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Elite Pharmaceuticals Q1 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Elite Pharmaceuticals Q1 Earnings Call Highlights

Key Points

Braskem Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  Quarry, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-YQuR80w6IvxjemEoWYDXbEZo.png?st=2023-10-15T10%3A03%3A37Z&se=2023-10-15T12%3A03%3A37Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-10-14T14%3A03%3A01Z&ske=2023-10-15T14%3A03%3A01Z&sks=b&skv=2021-08-06&sig=/3q45HS%2B7KQiNIRh0W63diwmt7u%2BeQQMkMTkhvmYMtE%3D
Braskem Q2 Earnings Call Highlights

Key Points

Can BMY's First CELMoD Approval Support Its Growth Strategy?
Can BMY's First CELMoD Approval Support Its Growth Strategy?

Bristol Myers Squibb BMY recently announced that the FDA has granted accelerated approval to iberdomide in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd).

The regimen

J.B. Hunt Sees Freight Recovery, Intermodal Pricing Upside Into 2027Photo, wide shot, wide-angle lens,  Investment company, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/81ff9992-3b90-4de2-ac95-7385f4698b55.png
J.B. Hunt Sees Freight Recovery, Intermodal Pricing Upside Into 2027

Key Points

Contango ORE Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens,  Coal mine, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/25526de2-54da-40ae-ba56-1e25dead3e81.png
Contango ORE Q2 Earnings Call Highlights

Key Points

Solana Company (HSDT) Reports Q2 Loss, Lags Revenue Estimates
Solana Company (HSDT) Reports Q2 Loss, Lags Revenue Estimates

Solana Company (HSDT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $79.73 per share a year ago. These figures

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.55 per share a year ago. These

Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates

Cerenome (CNSY) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.25 per share a year ago. These figures are

Sidus Space Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens,  Gas company, Midday, harsh overhead sunlight, directional sunlightt, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/07ff6859-914a-4fdd-8473-abdbac8978f6.png
Sidus Space Q2 Earnings Call Highlights

Key Points

Movano Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  IT consulting firm, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-uhXP0RHYYxDepjmHeSp1K8bF.png?st=2023-05-07T15%3A26%3A44Z&se=2023-05-07T17%3A26%3A44Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-07T16%3A18%3A55Z&ske=2023-05-08T16%3A18%3A55Z&sks=b&skv=2021-08-06&sig=4pcJOd8aEI1799liUV13F4ElqO7e4RZy8sa1PEeeNZA%3D
Movano Q2 Earnings Call Highlights

Key Points

Solana Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  Quarry, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-YQuR80w6IvxjemEoWYDXbEZo.png?st=2023-10-15T10%3A03%3A37Z&se=2023-10-15T12%3A03%3A37Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-10-14T14%3A03%3A01Z&ske=2023-10-15T14%3A03%3A01Z&sks=b&skv=2021-08-06&sig=/3q45HS%2B7KQiNIRh0W63diwmt7u%2BeQQMkMTkhvmYMtE%3D
Solana Q2 Earnings Call Highlights

Key Points

New Era Energy & Digital, Inc. (NUAI) Reports Q2 Loss, Misses Revenue Estimates
New Era Energy & Digital, Inc. (NUAI) Reports Q2 Loss, Misses Revenue Estimates

New Era Energy & Digital, Inc. (NUAI) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.21 per share a year ago

HIVE Digital Technologies (HIVE) Reports Q1 Loss, Lags Revenue Estimates
HIVE Digital Technologies (HIVE) Reports Q1 Loss, Lags Revenue Estimates

HIVE Digital Technologies (HIVE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.06 per share a year ago

InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates
InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.26 per share a year ago. These figures

Barfresh Food Group Inc. (BRFH) Reports Q2 Loss, Lags Revenue EstimatesPhoto, wide shot, wide-angle lens,  Specialty food store, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/7a8f69d5-c26e-46d9-b403-d3e5e9562eca.png
Barfresh Food Group Inc. (BRFH) Reports Q2 Loss, Lags Revenue Estimates

Barfresh Food Group Inc. (BRFH) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.06 per share a year ago. These

Prairie Operating Co. (PROP) Q2 Earnings Top Estimates
Prairie Operating Co. (PROP) Q2 Earnings Top Estimates

Prairie Operating Co. (PROP) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.18 per share a year ago

Catch the Monkey 29.08.2026

Catch the Monkey 29.08.2026

Flexible Solutions International Inc. (FSI) Reports Q2 Loss, Misses Revenue Estimates
Flexible Solutions International Inc. (FSI) Reports Q2 Loss, Misses Revenue Estimates

Flexible Solutions International Inc. (FSI) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of $0.01. This compares to earnings of $0.15 per share a year ago

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue EstimatesPhoto, wide shot, wide-angle lens,  Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago

Netflix: Ackman baut mit 3,15 Millionen Aktien aufPhoto, wide shot, wide-angle lens, soft focus,  IT consulting firm, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-uhXP0RHYYxDepjmHeSp1K8bF.png?st=2023-05-07T15%3A26%3A44Z&se=2023-05-07T17%3A26%3A44Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-07T16%3A18%3A55Z&ske=2023-05-08T16%3A18%3A55Z&sks=b&skv=2021-08-06&sig=4pcJOd8aEI1799liUV13F4ElqO7e4RZy8sa1PEeeNZA%3D
Netflix: Ackman baut mit 3,15 Millionen Aktien auf

Pershing Square Capital Management unter der Leitung von Bill Ackman hat eine neue Beteiligung…

Der Beitrag Netflix: Ackman baut mit 3,15 Millionen Aktien auf erschien zuerst auf kapitalmarktexperte